Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ANRS, Emerging Infectious Diseases
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Switzerland, Uganda, United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: HIV Infections
Phase 1: Chills|Headache|Post Acute COVID-19 Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EHVA_P01/ANRS_VRI08 | P2 |
Completed |
HIV Infections |
2025-11-04 |
|
| PrEPVacc | P2 |
Enrolling by invitation |
HIV Infections |
2024-12-31 |
|
| EHVA P01/ANRS VRI08 | P1 |
Active, not recruiting |
Post Acute COVID-19 Syndrome|HIV Infections|Headache|Chills |
2024-09-30 |